Maravai Lifesciences reports Q1 adjusted EPS (8c), consensus (7c)

Reports Q1 revenue $46.9M, consensus $44.01M. “Our first quarter revenue exceeded our guidance range, and our base business, which excludes revenue from high-volume CleanCap(R) for commercial vaccine programs, grew more than $4 million compared to the fourth quarter of 2024, reflecting solid execution and momentum across the business,” said Trey Martin, CEO, Maravai LifeSciences (MRVI). “Our team remains committed to our return-to-growth strategy amid a dynamic and shifting macroeconomic environment. We believe our customer focus, our differentiated technologies and GMP services supporting clients from discovery through commercialization give us the best position to continue navigating the evolving landscape and drive long-term value for Maravai.”